Should we really worry about "launch delays" of new drugs in OECD countries?
Eur J Health Econ
.
2007 Mar;8(1):1-3.
doi: 10.1007/s10198-006-0022-5.
Authors
Livio Garattini
,
Simone Ghislandi
PMID:
17186203
DOI:
10.1007/s10198-006-0022-5
No abstract available
Publication types
Editorial
MeSH terms
Bias
Cost Control
Developed Countries*
Drug Approval / economics
Drug Approval / organization & administration*
Europe
Humans